{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 462265189
| IUPAC_name = {(11''Z'')-11-[3-(dimethylamino)propylidene]-6,11-<br/>dihydrodibenzo[''b,e'']oxepin-2-yl}acetic acid
| image = Olopatadine.svg
<!--Clinical data-->
| tradename = Patanol and others
| Drugs.com = {{drugs.com|monograph|olopatadine-hydrochloride}}
| MedlinePlus = a602025
| pregnancy_category = C
| routes_of_administration = [[Eye drops|Ophthalmic]], intranasal, oral
<!--Pharmacokinetic data-->
| elimination_half-life = 3 hours
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 113806-05-6
| ATC_prefix = S01
| ATC_suffix = GX09
| ATC_supplemental = {{ATC|R01|AC08}}
| PubChem = 5281071
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00768
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4444528
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = D27V6190PM
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08293
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1189432
<!--Chemical data-->
| C=21 | H=23 | N=1 | O=3
| molecular_weight = 337.412 g/mol
| SMILES = O=C(O)Cc2ccc1OCc3c(C(\c1c2)=C\CCN(C)C)cccc3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8-
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = JBIMVDZLSHOPLA-LSCVHKIXSA-N
}}

'''Olopatadine''' is an [[antihistamine]] (as well as [[anticholinergic]] and [[mast cell]] stabilizer), sold as a [[prescription drug|prescription]] [[eye drop]] manufactured by [[Alcon]] in one of three strengths: 0.7% solution or '''Pazeo''' in the [[United States]],  0.2% solution or '''Pataday''' (also called '''Patanol S''' in some countries), and 0.1% or '''Patanol''' (also called '''Opatanol''' in some countries; Olopat in India). It is used to treat itching associated with allergic [[conjunctivitis]] (eye [[allergy|allergies]]).<ref name="Castillo">{{cite journal |authors=Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A |title= Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis |journal=Cochrane Database Syst Rev|volume=6 |pages= CD009566 |date=2015 |pmid= 26028608 |doi= 10.1002/14651858.CD009566.pub2}}</ref> A steroid-free<ref>[https://www.patanase.com/about/steroid-free-nasal-spray.aspx How PATANASE® Nasal Spray Works]</ref> [[nasal spray]] formulation is sold as '''Patanase''', which was approved by the FDA on April 15, 2008.<ref>[http://www.drugs.com/newdrugs/alcon-s-patanase-nasal-approved-fda-nasal-allergy-symptoms-942.html Drugs.com, Alcon's Patanase Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms]</ref> It is also available as an oral tablet in Japan under the tradename '''Allelock''', manufactured by Kyowa Hakko Kogyo.<ref name=KYOWA08>{{cite web | author = Kyowa Hakko Kogyo Co., Ltd. | year = 2007 | url = http://www.e-search.ne.jp/~jpr/PDF/KYOWA08.PDF |format=PDF| title = ALLELOCK Tablets 2.5 & ALLELOCK Tablets 5 (English) | accessdate = 2008-08-10}}</ref>

It should not be used to treat irritation caused by [[contact lenses]]. The usual dose for Patanol is 1 drop in each affected eye 2 times per day, with 6 to 8 hours between doses.  Both Pazeo and Pataday are dosed 1 drop in each eye daily.

There is potential for olopatadine as a treatment modality for steroid rebound (red skin syndrome).<ref>{{cite journal
|author1=Tamura T |author2=Matsubara M |author3=Hasegawa K |author4=Ohmori K |author5=Karasawa A. | year=2005 
| title=Olopatadine hydrochloride suppresses the rebound phenomenon after discontinuation of treatment with a topical steroid in mice with chronic contact hypersensitivity. | pmid=15649273 | doi=10.1111/j.1365-2222.2005.02147.x | volume=35 | issue=1 | journal=Clin Exp Allergy | pages=97–103}}</ref>

Olopatadine was developed by Kyowa Hakko Kogyo.<ref>{{cite web
| author=Kyowa Hakko Kogyo Co., Ltd.
| year=2002 | title=Company History | work=Company Information
| publisher=Kyowa Hakko Kogyo Co., Ltd. | url=http://www.kyowa-kirin.co.jp/english/company/history/index.html
| accessdate=16 September 2010 }}</ref>

==Side Effects==
Some known side effects include headache (7% of occurrence), eye burning and/or stinging (5%), blurred vision, dry eyes, foreign body sensation, [[hyperemia]], [[keratitis]], eyelid [[edema]], [[pruritus]], [[asthenia]], sore throat ([[pharyngitis]]), [[rhinitis]], [[sinusitis]], and taste perversion, vomitting.

==Chemistry==

===Synthesis===
[[File:Olopatadine synthesis.png|thumb|center|500px|Olopatadine synthesis:<ref>{{Cite journal | doi = 10.1021/jm00229a017| title = 6,11-Dihydro-11-oxodibenz[b,e]oxepinacetic acids with potent antiinflammatory activity| journal = Journal of Medicinal Chemistry| volume = 19| issue = 7| pages = 941–946| year = 1976| last1 = Ueno | first1 = K. | last2 = Kubo | first2 = S. | last3 = Tagawa | first3 = H. | last4 = Yoshioka | first4 = T. | last5 = Tsukada | first5 = W. | last6 = Tsubokawa | first6 = M. | last7 = Kojima | first7 = H. | last8 = Kasahara | first8 = A. }}</ref>]]

==References==
{{Reflist|2}}

==External links==
* [http://www.pataday.com Pataday website]
* [http://www.patanase.com Patanase website]
* [http://www.nlm.nih.gov/medlineplus/druginfo/meds/a602025.html Olopatadine Ophthalmic] via [[MedlinePlus]]

{{Antihistamines}}
{{Nasal preparations}}
{{Acetylcholine receptor modulators}}
{{Histamine receptor modulators}}
{{Tricyclics}}

[[Category:Acetic acids]]
[[Category:Amines]]
[[Category:Dibenzoxepins]]
[[Category:H1 receptor antagonists]]
[[Category:Mast cell stabilizers]]
[[Category:Muscarinic antagonists]]
[[Category:Oxygen heterocycles]]